Improvement of antibody responses by HIV envelope DNA and protein co-immunization

Vaccine

Volumn 32, Issue 4, 2014, Pages 507-513

  Pissani, Franco ^a,b,c,g   Malherbe, Delphine C ^c   Schuman, Jason T ^d   Robins, Harlan ^e   Park, Byung S ^b,c   Krebs, Shelly J ^b,c,g   Barnett, Susan W ^f   Haigwood, Nancy L ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d GE Healthcare Life Sciences   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Envelope based vaccine; HIV; Neutralizing antibodies

Indexed keywords

GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DNA VECTOR; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SURFACE PLASMON RESONANCE;

DNA+PROTEIN CO-IMMUNIZATION; ENVELOPE-BASED VACCINE; HIV; NEUTRALIZING ANTIBODIES;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY FORMATION; DNA, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; RABBITS; VACCINES, DNA;

EID: 84891630009     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.022     Document Type: Article

References (42)

1. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl J Med 2012, 366(April (14)):1275-1286.
2. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New Engl J Med 2009, 361(December (23)):2209-2220.
3. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6(February (2)):200-206.
4. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(February (2)):207-210.
5. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Donau O.K., Buckler C., et al. Transfer of neutralizing IgG to macaques 6h but not 24h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 2003, 100(December (25)):15131-15136.
6. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5(February (2)):204-210.
7. Huang K.H., Bonsall D., Katzourakis A., Thomson E.C., Fidler S.J., Main J., et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 2010, 1:102.
8. Sundling C., Forsell M.N., O'Dell S., Feng Y., Chakrabarti B., Rao S.S., et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010, 207(August (9)):2003-2017.
9. Zhao J., Lai L., Amara R.R., Montefiori D.C., Villinger F., Chennareddi L., et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009, 83(May (9)):4102-4111.
10. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473(May (7348)):523-527.
11. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482(February (7383)):89-93.
12. Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci USA 2013, 110(February (8)):2975-2980.
13. Blish C.A., Sather D.N., Sellhorn G., Stamatatos L., Sun Y., Srivastava I., et al. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol 2010, 84(March (5)):2573-2584.
14. Derby N.R., Kraft Z., Kan E., Crooks E.T., Barnett S.W., Srivastava I.K., et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006, 80(September (17)):8745-8762.
15. Morner A., Douagi I., Forsell M.N., Sundling C., Dosenovic P., O'Dell S., et al. Human immunodeficiency virus type 1 Env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 2009, 83(January (2)):540-551.
16. Nabel G.J., Kwong P.D., Mascola J.R. Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B: Biol Sci 2011, 366(October (1579)):2759-2765.
17. Vaine M., Duenas-Decamp M., Peters P., Liu Q., Arthos J., Wang S., et al. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol 2011, 85(May (10)):4927-4936.
18. Zolla-Pazner S., Kong X.P., Jiang X., Cardozo T., Nadas A., Cohen S., et al. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol 2011, 85(October (19)):9887-9898.
19. Pissani F., Malherbe D.C., Robins H., DeFilippis V.R., Park B., Sellhorn G., et al. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 2012, 30(Augu (37)):5519-5526.
20. Jaworski J.P., Krebs S.J., Trovato M., Kovarik D.N., Brower Z., Sutton W.F., et al. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PloS One 2012, 7(2):e31464.
21. Li J., Valentin A., Kulkarni V., Rosati M., Beach R.K., Alicea C., et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013, [April 26].
22. Huang Y., Krasnitz M., Rabadan R., Witten D.M., Song Y., Levine A.J., et al. A recoding method to improve the humoral immune response to an HIV DNA vaccine. PloS One 2008, 3(9):e3214.
23. Malherbe D.C., Doria-Rose N.A., Misher L., Beckett T., Puryear W.B., Schuman J.T., et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 2011, 85(June (11)):5262-5274.
24. Sellhorn G., Caldwell Z., Mineart C., Stamatatos L. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine 2009, 28(December (2)):430-436.
25. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009, 485:395-405.
26. Cheng-Mayer C., Brown A., Harouse J., Luciw P.A., Mayer A.J. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 1999, 73(July (7)):5294-5300.
27. Blish C.A., Nguyen M.A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med 2008, 5(January (1)):e9.
28. Vaine M., Wang S., Crooks E.T., Jiang P., Montefiori D.C., Binley J., et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008, 82(August (15)):7369-7378.
29. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77(October (20)):11244-11259.
30. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009, 83(January (2)):791-801.
31. Hoxie J.A. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135-152.
32. Sundling C., O'Dell S., Douagi I., Forsell M.N., Morner A., Lore K., et al. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J Virol 2010, 84(September (18)):9086-9095.
33. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010, 84(April (7)):3270-3279.
34. Dupuy L.C., Locher C.P., Paidhungat M., Richards M.J., Lind C.M., Bakken R., et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 2009, 27(June (31)):4152-4160.
35. Coban C., Kobiyama K., Aoshi T., Takeshita F., Horii T., Akira S., et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011, 11(December (6)):479-484.
36. Konishi E., Terazawa A., Imoto J. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 2003, 21(May (17-18)):1826-1832.
37. Simmons M., Murphy G.S., Kochel T., Raviprakash K., Hayes C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 2001, 65(November (5)):420-426.
38. Masalova O.V., Lesnova E.I., Pichugin A.V., Melnikova T.M., Grabovetsky V.V., Petrakova N.V., et al. The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization. Vaccine 2010, 28(February (8)):1987-1996.
39. Imoto J., Konishi E. Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol 2005, 18(1):205-212.
40. Wang S., Arthos J., Lawrence J.M., Van Ryk D., Mboudjeka I., Shen S., et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005, 79(June (12)):7933-7937.
41. Vaine M., Wang S., Hackett A., Arthos J., Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28(April (17)):2999-3007.
42. Sanders R.W., Derking R., Cupo A., Julien J.P., Yasmeen A., de Val N., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140. Expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013, 9(September (9)):e1003618.